Search Results

You are looking at 1 - 10 of 2,517 items for :

  • Refine by Access: All x
Clear All
Full access

Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic Breast Cancer: Analysis of ECOG-ACRIN E2112

Tarah J. Ballinger, Helga S. Marques, Gloria Xue, Richard Hoffman, Constantine Gatsonis, Fengmin Zhao, Kathy D. Miller, Joseph Sparano, and Roisin M. Connolly

function, quality of life, metabolism, and inflammation, and may impact outcome or toxicity in response to anticancer therapy. Low muscle mass (LMM) has been associated with reduced survival and increased toxicity in advanced solid tumor malignancies. 1

Full access

Beyond Median Overall Survival: Estimating Trends for Multiple Survival Scenarios in Patients With Metastatic Esophagogastric Cancer

Marieke Pape, Steven C. Kuijper, Pauline A.J. Vissers, Laurens V. Beerepoot, Geert-Jan Creemers, Hanneke W.M. van Laarhoven, and Rob H.A. Verhoeven

Background For patients with metastatic esophageal or gastric cancer, palliative systemic therapy is superior to best supportive care (BSC) in terms of survival and can improve quality of life. 1 – 3 After the introduction of chemotherapy

Full access

Treatment and Survival Among Patients With Colorectal Cancer in Sub-Saharan Africa: A Multicentric Population-Based Follow-Up Study

Lucia Hämmerl, Nikolaus C.S. Mezger, Tobias P. Seraphin, Walburga Yvonne Joko-Fru, Mirko Griesel, Jana Feuchtner, Franck Gnahatin, Freddy Houéhanou Rodrigue Gnangnon, Nathan Okerosi, Phoebe Mary Amulen, Rolf Hansen, Margaret Ziona Borok, Carla Carrilho, Brahima Mallé, Clausina Ahoui Apendi, Nathan G. Buziba, Edom Seife, Biying Liu, Rafael Mikolajczyk, Donald M. Parkin, Eva J. Kantelhardt, and Ahmedin Jemal

of underdiagnosis and underreporting of new cancer cases in the region. 12 However, there are limited data on receipt of guideline-concordant treatment and survival for patients diagnosed with CRC in SSA. The few existing studies are based on the

Full access

Validation of the PREDICT Prognostication Tool in US Patients With Breast Cancer

Nickolas Stabellini, Lifen Cao, Christopher W. Towe, Megan E. Miller, Artur H. Sousa-Santos, Amanda L. Amin, and Alberto J. Montero

,700 breast cancer–related deaths are expected. 2 Due to steady progress in early breast cancer diagnosis and treatment, 5-year overall survival (OS) continues to improve. 3 Accurate estimates of survival and the impact of different adjuvant therapies in

Full access

Cancer Patient Survival and Erythropoietin

John A. Glaspy

in gastric cancer cell growth, angiogenesis, and vessel maturation . J Natl Cancer Inst 2004 ; 96 : 946 – 956 . 20 Dunst J Kuhnt T Strauss HG . Anemia in cervical cancers: impact on survival, patterns of relapse, and association with

Full access

Merkel Cell Carcinoma: A Population Analysis on Survival

Vishwajith Sridharan, Vinayak Muralidhar, Danielle N. Margalit, Roy B. Tishler, James A. DeCaprio, Manisha Thakuria, Guilherme Rabinowits, and Jonathan D. Schoenfeld

carries a high risk of spreading to regional lymph nodes. Nodal recurrences and distant metastases are common, with limited survival for patients with advanced disease. 5 , 6 Treatment of localized MCC is variable, focusing on wide local excision

Full access

Conditional Survival and Cure of Patients With Colon or Rectal Cancer: A Population-Based Study

Seyed M. Qaderi, Paul W. Dickman, Johannes H.W. de Wilt, and Rob H.A. Verhoeven

Background Colorectal cancer (CRC) is the third most common cancer in the world. 1 , 2 Survival of patients with CRC has improved significantly because of earlier diagnosis and better treatment of the primary tumor and metastatic disease. 3

Full access

Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy

Kyuwan Lee, Aleksi Iukuridze, Tianhui He, Alysia Bosworth, Lanie Lindenfeld, Jennifer Berano Teh, Meagan Echevarria, Sophia Albanese, Liezl Atencio, Rusha Bhandari, F. Lennie Wong, Andrew S. Artz, Tanya Siddiqi, Liana Nikolaenko, Jasmine Zain, Matthew Mei, Geoffrey Shouse, Leslie L. Popplewell, Alex F. Herrera, L. Elizabeth Budde, Stephen J. Forman, and Saro H. Armenian

-threatening toxicities, such as cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). 1 – 4 Additionally, there is considerable prognostic variability after CAR T-cell therapy, including length of progression-free survival

Full access

Impact of Asian Race on Prognosis in De Novo Metastatic Prostate Cancer

Xudong Ni, Michael Luu, Weiwei Ma, Tingwei Zhang, Yu Wei, Stephen J. Freedland, Dingwei Ye, Timothy J. Daskivich, and Yao Zhu

addressing disparities between white and Black patients, 6 – 8 less is known about disparities related to the Asian race. 9 According to our knowledge, few studies have focused on the survival differences between Asian and white males with de novo

Full access

Impact of Surgical Resection on Survival Outcomes After Chemoradiotherapy in Anal Adenocarcinoma

Richard Li, Ashwin Shinde, Marwan Fakih, Stephen Sentovich, Kurt Melstrom, Rebecca Nelson, Scott Glaser, Yi-Jen Chen, Karyn Goodman, and Arya Amini

recommendations. No randomized trials exist, and the results of small retrospective case series have led to contradictory conclusions. A study by the Rare Cancer Network showed improved survival with CRT alone compared with surgery/radiotherapy (RT) or surgery